Method for detecting trace nitrosamine impurity N-nitroso-atomoxetine in atomoxetine hydrochloride

Through ultra-high performance liquid chromatography-mass spectrometry technology, combined with specific chromatography and mass spectrometry conditions, the problem of high detection limit of trace nitrosamine impurities in tomoxetine hydrochloride was solved, and the detection limit as low as 0.033ppm and 0.1ppm were achieved. The quantitative limit ensures the quality of the drug and the safety of the drug.

CN119044371APending Publication Date: 2024-11-29SHANDONG DYNE MARINE BIOTECHCAL PHARM HLDG CO LTD +1

Patent Information

Application Number
CN202411447288.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to accurately detect the trace amount of nitrosamine impurity N-nitroso-tomoxetine in tomoxetine hydrochloride, and the detection limit cannot achieve accurate detection with a content below 0.13 ppm.

Method used

UHP liquid chromatography-mass spectrometry technology, octadecylsilane bonded silica gel was used as filler through the chromatographic column, and gradient elution was used in aqueous formic acid solution and acetonitrile solution, combined with electrospray ion source and multi-reaction detection (MRM) The model enables rapid and accurate detection of trace nitrosamine impurities in tomoxetine hydrochloride.

Benefits of technology

The detection limit for trace nitrosamine impurities in tomoxetine hydrochloride is 0.033ppm and the quantification limit is 0.1ppm, which improves the accuracy and sensitivity of the detection and ensures drug quality control and drug safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044371A_ABST
    Figure CN119044371A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting trace nitrosamine impurity N-nitroso-atomoxetine in atomoxetine hydrochloride, and belongs to the technical field of medicine detection. The method comprises the following steps: dissolving atomoxetine hydrochloride in a diluent to obtain a test solution; carrying out analysis and detection on the test solution by adopting ultra-high performance liquid chromatography-mass spectrometry; chromatographic conditions are as follows: octadecylsilane chemically bonded silica is taken as a filling agent of a chromatographic column; a formic acid aqueous solution is used as a mobile phase A, a formic acid acetonitrile solution is used as a mobile phase B, and gradient elution is performed; mass spectrum conditions include that an ion source is an electrospray ion source, a scanning mode is a positive ion mode, and a detection mode is multi-reaction detection (MRM). When the method is used for detection, the sample pretreatment operation is simple, the detection time is short, the quantification limit is as low as 0.1 ppm, the detection limit is as low as 0.033 ppm, the sensitivity is high, and the content of trace N-nitroso-atomoxetine in the sample can be accurately and quickly detected.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting trace nitrosamine impurity N-nitroso-tomoxetine in atomoxetine hydrochloride. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Atomoxetine Hydrochloride has the following chemical structure:

[0004]

[0005] Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor used to treat attention deficit hyperactivity disorder in children. Compared with similarly effective central nervous system stimulant drugs, it has the advantages of strong selectivity and good safety. However, the nitrosamine impurity N-nitroso-atomoxetine is generated during the synthesis of atomoxetine hydrochloride. Nitrosamine compounds are known high-risk carcinogens. In recent years, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the National Medical Products Administration (NMPA) have successively released documents related to nitrosamine impurities. According to the latest FDA regulations, the recommended acceptable intake of nitrosamine impurities in atomoxetine hydrochloride is 100 ng / day, and the maximum daily dose of atomoxetine hydrochloride is 100 mg / day. The calculated limit of nitrosamine impurities is not more than 1 ppm.

[0006] Conventional detection methods for compounds mainly include gas chromatography, liquid chromatography, gas chromatography-mass spectrometry, and liquid chromatography-mass spectrometry. Gas chromatography and liquid chromatography are more strict in sample processing. If the sample is complex, there is a poor separation degree and the target compound chromatographic peak cannot be accurately determined, which causes unreliable results and large interference. Gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry mainly use chromatographic columns for separation. The mass spectrometry is qualitative and quantitative according to the measured molecular weight and the intensity of the molecular weight substance. Compared with gas chromatography and liquid chromatography, chromatography and mass spectrometry technology can better complete the qualitative and quantitative analysis of complex samples. For example, patent CN106596780A discloses a method for detecting the content of multiple antibiotics in water by high pressure liquid chromatography-mass spectrometry. The content of multiple antibiotics in water environment samples is obtained by solid phase extraction enrichment and concentration, high pressure liquid chromatography-mass spectrometer detection, and analysis. The accuracy is less than 1ppm and the detection limit is 0.0001-0.005ppm. The acceptable limit of nitrosamine compounds in the human body is relatively small, and the detection and control of trace impurities are difficult. At present, there is no report on the detection method of trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride raw materials and preparations.

[0007] Therefore, rapid and accurate detection of trace nitrosamine impurity N-nitroso-tomoxetine in atomoxetine hydrochloride is of great significance for quality control of atomoxetine hydrochloride and its preparations and ensuring drug safety. Summary of the invention

[0008] In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a method for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride. The inventors have found that if only ultra-high performance liquid chromatography is used to detect nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride, the detection limit is high, and the accurate detection of nitrosamine impurities N-nitroso-tomoxetine with a content lower than 0.13ppm cannot be achieved. In this regard, the present invention provides a method for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride by ultra-high performance liquid chromatography-mass spectrometry, the detection limit of the detection method is 0.033ppm, the quantitative limit is 0.100ppm, and the trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride raw materials are achieved. Rapid and accurate detection.

[0009] In order to achieve the above object, the technical solution of the present invention is:

[0010] The first aspect of the present invention provides a method for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride, comprising the following steps:

[0011] Dissolving atomoxetine hydrochloride in a diluent to obtain a test solution; analyzing and detecting the test solution by ultra-high performance liquid chromatography-mass spectrometry;

[0012] The chromatographic conditions include: the chromatographic column uses octadecylsilane bonded silica gel as a filler; formic acid aqueous solution is used as mobile phase A, formic acid acetonitrile solution is used as mobile phase B, and gradient elution is performed;

[0013] The mass spectrometry conditions included: the ion source was an electrospray ion source, the scanning mode was a positive ion mode, and the detection mode was multiple reaction detection MRM;

[0014] The trace amount means that the detection method can identify and detect N-nitroso-atomoxetine at the ppm level or below.

[0015] In some embodiments of the present invention, the detection method further comprises a quantitative analysis step;

[0016] Wherein, the quantitative analysis step comprises: dissolving N-nitroso-atomoxetine in a diluent to obtain a reference solution, and analyzing the reference solution using the above-mentioned detection method to obtain a chromatogram of the reference solution;

[0017] The content of N-nitroso-tomoxetine in atomoxetine hydrochloride was calculated by the peak areas in the chromatograms of the test solution and the reference solution.

[0018] In some embodiments of the present invention, the mass spectrometry conditions include: quantitative detection, Q1 is 285.0Da, Q3 is 177.2Da, DP is 85±2V, and CE is 12±2V.

[0019] Preferably, DP is 85 V and CE is 12 V. Under this condition, the detection effect is best.

[0020] In some embodiments of the present invention, the detection method for detecting trace nitrosamine impurity N-nitroso-tomoxetine in atomoxetine hydrochloride has a quantitative limit of 0.1 ppm, a detection limit of 0.033 ppm, a linear range of 0.1-2 ppm, and a linear equation of y=245124.7629x+5273.9731, r>0.999.

[0021] It should be noted that the content of trace N-nitroso-tomoxetine in atomoxetine hydrochloride can be calculated by the external standard method, and the calculation formula is as follows:

[0022]

[0023] Where:

[0024] A U --N-nitroso-atomoxetine peak area in the test solution;

[0025] A S--N-nitroso-atomoxetine peak area in the reference solution;

[0026] C S --N-nitroso-atomoxetine concentration in the reference solution, ng / mL;

[0027] C U --Concentration of test solution, mg / mL.

[0028] In some embodiments of the present invention, the structure of N-nitroso-atomoxetine is as follows:

[0029]

[0030] It should be noted that the molecular formula of N-nitroso-atomoxetine is C 17 H 20 N2O2, the reference substance was purchased from QUALITY CONTROL CHEMICALS INC, USA, QCC Cat No.: QA150923.

[0031] In some embodiments of the present invention, the diluent is a methanol aqueous solution, preferably a 70% methanol aqueous solution.

[0032] It should be noted that 70% in the 70% methanol aqueous solution is a volume percentage, and the volume ratio of methanol to water in the 70% methanol aqueous solution is 7:3.

[0033] In some embodiments of the present invention, the concentration of the test solution is 0.9-1.1 mg / mL, preferably 1 mg / mL.

[0034] In some embodiments of the present invention, the mobile phase A is a 0.09-0.11% formic acid aqueous solution, preferably a 0.1% formic acid aqueous solution.

[0035] In some embodiments of the present invention, the mobile phase B is a 0.09-0.11% formic acid acetonitrile solution, preferably a 0.1% formic acid acetonitrile solution.

[0036] It should be noted that the 0.09-0.11% is a volume percentage, and a 0.09-0.11% formic acid aqueous solution is a solution containing 0.9-1.1 mL of formic acid per 1000 mL of solution, and a 0.09-0.11% formic acid acetonitrile solution is a solution containing 0.9-1.1 mL of formic acid per 1000 mL of solution.

[0037] In some embodiments of the present invention, the gradient elution is as follows, in volume percentage:

[0038] 0-1min, mobile phase A 80%, mobile phase B 20%;

[0039] From 1 to 8 min, mobile phase A was reduced from 80% to 10%, and mobile phase B was increased from 20% to 90%;

[0040] 8.1~10min, mobile phase A 80%, mobile phase B 20%.

[0041] In some embodiments of the present invention, the chromatographic conditions further include:

[0042] The flow rate is 0.35-0.45 mL / min, preferably 0.4 mL / min;

[0043] The column temperature is 35-45°C, preferably 40°C;

[0044] The chromatographic column was Hypersil GOLD, 100 mm × 2.1 mm, 1.9 μm;

[0045] The injector temperature was 4 °C.

[0046] In some embodiments of the present invention, the mass spectrometer is a triple quadrupole mass spectrometer, and after gradient elution, triple quadrupole mass spectrometer detection is used.

[0047] In some embodiments of the present invention, the mass spectrometry conditions further include:

[0048] IS voltage is 5500V; atomizer GAS1 is 55psi; auxiliary gas GAS2 is 20psi; ion source temperature is 550℃; collision gas: 8. The above mass spectrometry conditions are the optimal technical conditions in the technical solution of the present invention. Under these conditions, the detection effect is good. Those skilled in the art can make corresponding adjustments according to actual needs to obtain excellent detection effects.

[0049] In some embodiments of the present invention, the mass spectrometry conditions further include: qualitative detection, Q1 is 285.0Da, Q3 is 117.0Da, DP is 84±2V, and CE is 27±2V.

[0050] Preferably, DP is 84 V and CE is 27 V. Under this condition, the detection effect is best.

[0051] In some embodiments of the present invention, the chromatographic conditions are: the chromatographic column is filled with octadecylsilane bonded silica gel; the chromatographic column is Hypersil GOLD, 100mm×2.1mm, 1.9μm; 0.1% formic acid aqueous solution is used as mobile phase A, 0.1% formic acid acetonitrile solution is used as mobile phase B, gradient elution; the flow rate is 0.4mL / min, the column temperature is 40°C, the injection volume is 5μL, and the injector temperature is 4°C;

[0052] The mass spectrometry conditions are as follows: the mass spectrometer is a triple quadrupole mass spectrometer, the ion source is an electrospray ion source, the scanning mode is a positive ion mode, and the detection mode is multiple reaction detection MRM; the IS voltage is 5500V; the nebulizer GAS1 is 55psi; the auxiliary gas GAS2 is 20psi; the ion source temperature is 550°C; the collision gas: 8; for qualitative detection, Q1 is 285.0Da, Q3 is 117.0Da, DP is 84V, and CE is 27V; for quantitative detection, Q1 is 285.0Da, Q3 is 177.2Da, DP is 85V, and CE is 12V.

[0053] The second aspect of the present invention provides a method for evaluating the quality of atomoxetine hydrochloride, using the above-mentioned detection method.

[0054] The beneficial effects of the present invention are:

[0055] The present invention provides a method for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride. The present invention proposes for the first time to use ultra-high performance liquid chromatography-mass spectrometry to analyze and detect trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride, providing a strong guarantee for effectively controlling the quality of drugs and ensuring the safety of drugs. The ultra-high performance liquid chromatography-tandem mass spectrometry technology of the present invention is used to detect trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride raw materials, with high selectivity, good method specificity, a quantitative limit as low as 0.1ppm, a detection limit as low as 0.033ppm, and a high method sensitivity. The content of trace nitrosamine impurities N-nitroso-tomoxetine in samples can be quickly and accurately detected, effectively reducing the analysis cost. The present invention also verifies the accuracy of nitrosamine impurities in the range of 50% to 150% of the limit concentration (1 ppm), and the recovery rate of N-nitroso-tomoxetine is between 75% and 120%, with good accuracy; it also verifies the linearity of N-nitroso-tomoxetine in the range of 10% to 200% of the limit concentration, and N-nitroso-tomoxetine has r>0.999 in the above range, with good linearity. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0057] Figure 1 This is the blank solution spectrum of Example 1 of the present invention;

[0058] Figure 2 This is the N-nitroso-atomoxetine impurity reference solution spectrum of Example 1 of the present invention;

[0059] Figure 3 The sample solution spectrum of Example 1 of the present invention;

[0060] Figure 4 This is the system applicability solution spectrum of Example 1 of the present invention. DETAILED DESCRIPTION

[0061] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0062] Example 1: Specificity

[0063] 1-1 Solution Preparation

[0064] Dilution solution (blank solution): Measure 700 mL of methanol and 300 mL of water and mix well.

[0065] N-nitroso-atomoxetine impurity reference solution: Accurately measure an appropriate amount of N-nitroso-atomoxetine impurity reference solution and quantitatively dilute it with diluent to make a 1 ng / mL solution.

[0066] Test solution: Take about 10 mg of atomoxetine hydrochloride raw material, place it in a 10 mL volumetric flask, add diluent to dissolve and dilute to the scale, and shake well.

[0067] System suitability solution: Take about 10 mg of atomoxetine hydrochloride raw material, place it in a 10 mL volumetric flask, add an appropriate amount of N-nitroso-tomoxetine impurity, add diluent to dissolve by ultrasonic and dilute to the scale, shake well, and prepare a mixed solution containing about 1 mg of atomoxetine hydrochloride and 1 ng of N-nitroso-tomoxetine impurity per 1 mL.

[0068] 1-2 Chromatographic and mass spectrometry conditions

[0069] Column: Hypersil GOLD, 100 mm × 2.1 mm, 1.9 μm;

[0070] Mobile Phase:

[0071] Mobile phase A was 0.1% formic acid in water;

[0072] Mobile phase B was 0.1% formic acid acetonitrile;

[0073] Elution method: gradient elution;

[0074] Time (min) Mobile phase A (%) Mobile phase B (%) 0~1 80 20 1~8 80~10 20~90 8.1~10 80 20

[0075] Flow rate: 0.4 mL / min;

[0076] The column temperature was 40°C;

[0077] The injection volume was 5 μL;

[0078] The injector temperature was 4 °C.

[0079] Ion source: ESI source, positive ion scanning;

[0080] Scanning mode: MRM acquisition mode;

[0081] IS voltage: 5500V(+);

[0082] Atomizer GAS1: 55psi; Auxiliary gas GAS2: 20psi;

[0083] Ion source temperature: 550°C; collision gas: 8;

[0084] Mass spectrometry parameters

[0085] Q1(Da) Q3(Da) DP(V) CE(V) Remark 285.0 177.2 85 12 Quantification 285.0 117.0 84 27 Qualitative

[0086] 1-3 Experimental conclusion:

[0087] Accurately measure the above solution, inject it into the ultra-high performance liquid chromatography-mass spectrometer, and record the chromatogram. The results are shown in Table 1, and the blank solution spectrum is shown in Figure 1 , N-nitroso-atomoxetine impurity reference solution see Figure 2 , test solution see Figure 3 , System Suitability Solutions See Figure 4 .

[0088] Table 1 System suitability and impurity localization results

[0089]

[0090] Conclusion: The blank solvent and the test solution do not interfere with the detection of N-nitroso-atomoxetine impurities, and the specificity of the present invention is good.

[0091] Example 2: Linearity and range experiments

[0092] 2-1 Solution preparation

[0093] Accurately weigh an appropriate amount of N-nitroso-atomoxetine impurity reference substance and prepare a series of concentration linear investigation solutions with concentrations ranging from the quantitative limit (0.1 ppm in Example 3) to about 2 ppm.

[0094] 2-2 Chromatographic and mass spectrometric conditions are the same as those in Example 1.

[0095] 2-3 Conclusion:

[0096] The above solution was accurately measured and injected into an ultra-high performance liquid chromatography-mass spectrometer to record the chromatogram. The results are shown in Table 2. A linear regression equation was made with concentration as the abscissa and peak area as the ordinate.

[0097] Table 2 Results of linearity test of N-nitroso-atomoxetine impurities

[0098]

[0099] Conclusion: Within the determination range (0.1-2ppm), the linear relationship of N-nitroso-atomoxetine impurity is good and meets the methodological requirements.

[0100] Example 3: Limit of Quantitation and Limit of Detection

[0101] 3-1 Solution preparation

[0102] The linear solution in Example 2 was diluted step by step, and the concentration when the signal-to-noise ratio S / N≈3 was taken as the detection limit, and the concentration when S / N≈10 was taken as the quantification limit.

[0103] 3-2 Chromatographic and mass spectrometric conditions are the same as those in Example 1.

[0104] 3-3 Conclusion:

[0105] The above solution was accurately measured and injected into the ultra-high performance liquid chromatography-mass spectrometer to record the chromatogram. The results are shown in Table 3.

[0106] Table 3 Quantitation limit and detection limit test results

[0107]

[0108] Conclusion: The quantitative limit of N-nitroso-tomoxetine impurity is lower than the impurity reporting limit of this product (1 ppm). The detection limit (0.033 ppm) and quantitative limit (0.100 ppm) of the present invention both meet the requirements for quantitative detection of N-nitroso-tomoxetine impurities in the test sample, and the method has high sensitivity.

[0109] Example 4: Accuracy Experiment

[0110] The accuracy was investigated through recovery test, and the study covered the limit concentration range of 50% to 150%.

[0111] 4-1 Solution preparation

[0112] N-nitroso-atomoxetine impurity stock solution (100 μg / mL): Take an appropriate amount of N-nitroso-atomoxetine impurity reference substance, accurately weigh it, add 70% methanol to dissolve it and dilute it to make a 100 μg / mL solution.

[0113] N-nitroso-atomoxetine impurity stock solution (1 μg / mL): Accurately measure 1 mL of N-nitroso-atomoxetine impurity stock solution (100 μg / mL), place in a 100 mL volumetric flask, dilute to the scale with 70% methanol, and shake well.

[0114] N-nitroso-atomoxetine impurity stock solution (10 ng / mL): Accurately measure 1 mL of N-nitroso-atomoxetine impurity stock solution (1 μg / mL), place in a 100 mL volumetric flask, dilute to the scale with 70% methanol, and shake well.

[0115] Reference solution: Accurately measure 1 mL of N-nitroso-atomoxetine impurity stock solution (10 ng / mL), place in a 10 mL volumetric flask, dilute to the mark with 70% methanol, and shake well.

[0116] Accuracy solution: Weigh approximately 10 mg of each atomoxetine hydrochloride bulk drug into 10 mL volumetric flasks, accurately measure 0.5 mL, 1.0 mL and 1.5 mL of N-nitroso-atomoxetine impurity stock solution (10 ng / mL), dissolve in diluent and dilute to the scale, shake well, and prepare 3 replicates in parallel for each spiked concentration level.

[0117] 4-2 Chromatographic and mass spectrometric conditions are the same as those in Example 1.

[0118] 4-3 Conclusion:

[0119] The above solution was accurately measured and injected into the ultra-high performance liquid chromatography-mass spectrometer. The chromatogram was recorded and calculated by the peak area according to the external standard method. The accuracy results are shown in Table 4.

[0120] Table 4 Accuracy test results

[0121]

[0122]

[0123] Conclusion: Under 50%, 100% and 150% accuracy solutions, the recovery rates of N-nitroso-atomoxetine impurities were all between 75% and 120%, with an RSD of 6.91%. The test results showed that the accuracy of the present invention was good.

[0124] Example 5: Precision Experiment

[0125] 5-1 Solution preparation

[0126] Weigh about 10 mg of atomoxetine hydrochloride raw material, place in a 10 mL volumetric flask, add 1.0 mL of N-nitroso-atomoxetine impurity stock solution (10 ng / mL), add diluent to dissolve and dilute to the scale, shake well, and prepare 6 copies in parallel.

[0127] Control solution: same as Example 4.

[0128] 5-2 Chromatographic and mass spectrometric conditions are the same as those in Example 1.

[0129] 5-3 Conclusion:

[0130] Accurately measure the above solution, inject it into the ultra-high performance liquid chromatography-mass spectrometer, record the chromatogram, calculate the impurity content, and the precision results are shown in Table 5.

[0131] Table 5 Precision test results

[0132] sample N-Nitroso-atomoxetine (ppm) 1 0.98 2 0.98 3 0.96 4 0.92 5 0.92 6 0.92 average(%) 0.95 RSD(%) 2.9

[0133] Conclusion: The test results of 6 replicate sample solutions prepared in parallel showed that the RSD value of N-nitroso-atomoxetine impurity was less than 10%, which proved that the present invention had good repeatability.

[0134] Example 6: Solution stability experiment

[0135] 6-1 Solution preparation

[0136] Take the test solution and the reference solution in Example 1, place them in a sample injector at 4°C, and inject and test them at different time points.

[0137] 6-2 Chromatographic and mass spectrometric conditions are the same as those in Example 1.

[0138] 6-3 Conclusion:

[0139] The above solution was accurately measured and injected into the ultra-high performance liquid chromatography-mass spectrometer to record the chromatogram. The solution stability results are shown in Table 6.

[0140] Table 6 Solution stability test results

[0141]

[0142] Conclusion: After the test solution and the reference solution were placed at 4°C for 9 hours, the peak area of ​​N-nitroso-atomoxetine impurity did not change significantly, indicating that the test solution and the reference solution were stable within 9 hours.

[0143] Example 7: Durability Test

[0144] Durability refers to the degree to which the test results are not affected by slight changes in the chromatographic conditions. The preparation of the spiked test solution (system suitability solution), the test solution and the reference solution is the same as in Example 1. On the basis of the test conditions of Example 1, the durability of the test method is changed under the conditions of temperature, flow rate and initial ratio of mobile phase B. The test results are shown in Table 7.

[0145] Table 7 Durability test results

[0146]

[0147]

[0148] Conclusion: When changing (column temperature ±5°C, flow rate ±0.05mL / min, initial proportion of mobile phase B ±5%), the blank solution and the test solution did not interfere with the determination of N-nitroso-atomoxetine impurities, none of them were detected in the test samples, and the recovery rate of the spiked test samples met the requirements. The durability of the method of the present invention is good.

[0149] Based on the above experimental results, the detection method of the present invention is used to detect the trace nitrosamine impurity N-nitroso-tomoxetine in the atomoxetine hydrochloride raw material. The blank solvent and the main component do not interfere with the detection of nitrosamine impurities. The method has strong specificity, high sensitivity, and the detection limit is as low as 0.033ppm and the quantitative limit is as low as 0.1ppm. It is quantitatively accurate. It is of great significance to ensure the safety of medication for the quality control of atomoxetine hydrochloride and its preparations.

[0150] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride, characterized in that: The steps include: Dissolving atomoxetine hydrochloride in a diluent to obtain a test solution; analyzing and detecting the test solution by ultra-high performance liquid chromatography-mass spectrometry; The chromatographic conditions include: the chromatographic column uses octadecylsilane bonded silica gel as a filler; formic acid aqueous solution is used as mobile phase A, formic acid acetonitrile solution is used as mobile phase B, and gradient elution is performed; The mass spectrometry conditions included: the ion source was an electrospray ion source, the scanning mode was a positive ion mode, and the detection mode was multiple reaction detection MRM; The trace amount means that the detection method can identify and detect N-nitroso-atomoxetine at the ppm level or below.

2. The detection method according to claim 1, characterized in that The detection method also includes a quantitative analysis step; Wherein, the quantitative analysis step comprises: dissolving N-nitroso-atomoxetine in a diluent to obtain a reference solution, and analyzing the reference solution using the detection method of claim 1 to obtain a chromatogram of the reference solution; The content of N-nitroso-tomoxetine in atomoxetine hydrochloride was calculated by the peak areas in the chromatograms of the test solution and the reference solution.

3. The detection method according to claim 2, characterized in that The mass spectrometry conditions include: quantitative detection, Q1 is 285.0Da, Q3 is 177.2Da, DP is 85±2V, CE is 12±2V; Preferably, DP is 85V and CE is 12V.

4. The detection method according to claim 2 or 3, characterized in that: The detection method has a quantitative limit of 0.1 ppm for detecting trace nitrosamine impurities N-nitroso-tomoxetine in atomoxetine hydrochloride, a detection limit of 0.033 ppm, a linear range of 0.1-2 ppm, and a linear equation of y=245124.7629x+5273.9731, r>0.

999.

5. The detection method according to claim 1 or 2, characterized in that: The diluent is a methanol aqueous solution, preferably a 70% methanol aqueous solution; Preferably, the concentration of the test solution is 0.9-1.1 mg / mL, preferably 1 mg / mL.

6. The detection method according to claim 1, characterized in that The mobile phase A is 0.09-0.11% formic acid aqueous solution, preferably 0.1% formic acid aqueous solution; Preferably, the mobile phase B is a 0.09-0.11% formic acid acetonitrile solution, preferably a 0.1% formic acid acetonitrile solution.

7. The detection method according to claim 1, characterized in that In volume percentage, the gradient elution is as follows: 0-1min, mobile phase A 80%, mobile phase B 20%; From 1 to 8 min, mobile phase A was reduced from 80% to 10%, and mobile phase B was increased from 20% to 90%; 8.1~10min, mobile phase A 80%, mobile phase B 20%.

8. The detection method according to claim 1, characterized in that The chromatographic conditions also include: The flow rate is 0.35-0.45 mL / min, preferably 0.4 mL / min; The column temperature is 35-45°C, preferably 40°C; The chromatographic column was Hypersil GOLD, 100 mm × 2.1 mm, 1.9 μm; The injector temperature was 4°C; Preferably, the mass spectrometer is a triple quadrupole mass spectrometer, and after gradient elution, triple quadrupole mass spectrometer detection is used; Preferably, the mass spectrometry conditions further include: IS voltage is 5500V; nebulizer GAS1 is 55psi; auxiliary gas GAS2 is 20psi; ion source temperature is 550℃; collision gas: 8; Preferably, in qualitative detection, Q1 is 285.0Da, Q3 is 117.0Da, DP is 84±2V, and CE is 27±2V. More preferably, DP is 84V and CE is 27V.

9. The detection method according to claim 1, characterized in that: The chromatographic conditions are as follows: the chromatographic column is filled with octadecylsilane bonded silica gel; the chromatographic column is Hypersil GOLD, 100 mm×2.1 mm, 1.9 μm; 0.1% formic acid aqueous solution is used as mobile phase A, 0.1% formic acid acetonitrile solution is used as mobile phase B, and gradient elution is performed; the flow rate is 0.4 mL / min, the column temperature is 40° C., the injection volume is 5 μL, and the injector temperature is 4° C.; The mass spectrometry conditions are as follows: the mass spectrometer is a triple quadrupole mass spectrometer, the ion source is an electrospray ion source, the scanning mode is a positive ion mode, the detection mode is a multiple reaction detection MRM; the IS voltage is 5500V; the nebulizer GAS1 is 55psi; The auxiliary gas GAS2 was 20psi; the ion source temperature was 550℃; the collision gas was 8; for qualitative detection, Q1 was 285.0Da, Q3 was 117.0Da, DP was 84V, and CE was 27V; for quantitative detection, Q1 was 285.0Da, Q3 was 177.2Da, DP was 85V, and CE was 12V.

10. A quality assessment method for atomoxetine hydrochloride, characterized in that: The detection method according to any one of claims 1 to 9 is adopted.

Citation Information

Patent Citations

  • Method for detecting contents of various antibiotics in water by combined use of high pressure liquid chromatography and mass spectrum

    CN106596780A

Cited By

  • Method for detecting N-nitroso ambroxol in medicine by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry)

    CN119936272A

  • A Method for Detecting N-Nitrosol Ambroxol in Drugs by LC-MS / MS

    CN119936272B

  • Method for detecting N-nitrosoduloxetine residue in duloxetine hydrochloride enteric-coated tablet

    CN120801575A

  • Method for detecting content of genotoxic impurity N-nitrosopropafenone in propafenone hydrochloride injection

    CN121453981A